Teduglutide improves liver chemistries in short bowel syndrome–associated intestinal failure: Post hoc analysis
Nutrition in Clinical Practice · 2024
DOI: 10.1002/ncp.11139 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrition in Clinical Practice, 2024. Verfasst von Dejan Micic und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Peptides, Liver, Gastrointestinal Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by Takeda Pharmaceuticals USA, Inc..
Abstract (Originalsprache)
Background
Chronic hepatic complications are common in patients with short bowel syndrome–associated intestinal failure (SBS‐IF). Teduglutide, a glucagon‐like peptide‐2 analogue, demonstrated efficacy in reducing parenteral nutrition and/or intravenous fluid dependence among patients with SBS‐IF in phase 3 clinical studies.
Methods
This was a post hoc analysis of pooled data from two separate randomized, double‐blind, placebo‐controlled, multinational phase 3 clinical studies. Adult patients with SBS‐IF with parenteral nutrition and/or intravenous fluid dependence without liver disease at baseline were randomized to treatment with the glucagon‐like peptide‐2 analogue teduglutide (0.05 or 0.10 mg/kg/day) or placebo subcutaneously once daily for 24 weeks. Mixed‐effects models assessed the baseline predictors of change in liver chemistries.
Results
Between baseline and week 24, teduglutide treatment ( n = 109) was associated with least squares mean reductions in aspartate aminotransferase (–7.51 IU/L; P = 0.014), alanine aminotransferase (–12.15 IU/L; P = 0.002), and bilirubin (–5.03 µmol/L [–0.057 mg/dl]; P < 0.001) compared with that of the placebo ( n = 59). These values were independent of reductions in parenteral nutrition and/or intravenous fluid dependence.
Conclusion
Teduglutide treatment was associated with reductions in liver chemistries by week 24, which is beneficial for patients with SBS‐IF beyond improvements in parenteral nutrition and/or intravenous fluid dependence. Future studies should examine how long‐term teduglutide might mitigate the risk of liver disease in patients with SBS‐IF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Illinois, USA.
- Takeda Pharmaceuticals, USA, Inc, Lexington, Massachusetts, USA.
Förderung
- This study was funded by Takeda Pharmaceuticals USA, Inc.
Zitieren
APA
Micic, D., Robinson, I., Kidd, T., Terreri, B., & Raphael, B. P. (2024). Teduglutide improves liver chemistries in short bowel syndrome–associated intestinal failure: Post hoc analysis. Nutrition in Clinical Practice. https://doi.org/10.1002/ncp.11139
Vancouver
Micic D, Robinson I, Kidd T, Terreri B, Raphael BP. Teduglutide improves liver chemistries in short bowel syndrome–associated intestinal failure: Post hoc analysis. Nutrition in Clinical Practice. 2024. doi:10.1002/ncp.11139
BibTeX
@article{Micic2024,
author = {Micic, Dejan and Robinson, Ian and Kidd, Tanya and Terreri, Brian and Raphael, Bram P},
title = {Teduglutide improves liver chemistries in short bowel syndrome–associated intestinal failure: Post hoc analysis},
journal = {Nutrition in Clinical Practice},
year = {2024},
doi = {10.1002/ncp.11139}
}
EUVIMED